Results 251 to 260 of about 1,240,974 (338)

TriCON: A Carbon‐Based Triple‐Modal Nanoplatform for Pancreatic Cancer Therapy

open access: yesAdvanced Science, EarlyView.
We developed TriCON, a triple‐modality nanotherapeutic platform, to treat pancreatic ductal adenocarcinoma (PDAC) by synergizing gene editing, chemotherapy, and immunotherapy. TriCON utilizes CRISPR/Cas9 to target the poliovirus receptor (PVR), combined with nano‐encapsulated doxorubicin and checkpoint blockade. This approach achieved significant tumor
Xinyu Peng   +9 more
wiley   +1 more source

Metabolic Reprogramming of T Cells by Dual UCP2 and IL‐17 Blockade Enhances Immunity Against Pancreatic Cancer

open access: yesAdvanced Science, EarlyView.
This study demonstrates that dual UCP2/IL‐17 blockade reprograms T‐cell metabolism to overcome PDAC immunosuppression. Genipin‐mediated UCP2 inhibition enhances CD8⁺ T‐cell IFN‐γ via IL‐12R/STAT4/mTOR signaling and mitochondrial OXPHOS. Combined IL‐17 depletion amplifies Tc1/Th1 responses, reduces MDSCs, and prolongs survival in PDAC models ...
Chuan‐Teng Liu   +11 more
wiley   +1 more source

Ultrasound‐Boosted Liposomal Prodrug Overcomes Age‐Associated Biodistribution Disparity in Pediatric Solid Tumor Therapy

open access: yesAdvanced Science, EarlyView.
The age‐associated disparity of nanocarrier biodistribution limits the nanotherapeutics of childhood solid tumors. This study developed an ultrasound‐activated liposomal prodrug (CSCPTL) to overcome the age‐associated disparity of off‐target distribution.
Danfei Chen   +8 more
wiley   +1 more source

Immunomodulatory Hydrogel Coating with SeNPs and Lithium Silicate Synergistically Promotes Osseointegration and Prevents Infection on Titanium Implants

open access: yesAdvanced Science, EarlyView.
This study introduces a multifunctional hydrogel coating (Lap‐CMCSMA/GelMA@SeNPs) that scavenges ROS, modulates immune responses, and shows strong antibacterial activity. It effectively restores the peri‐implant microenvironment. The coating exhibits excellent biocompatibility and promotes osteogenic differentiation.
Su Jiang   +7 more
wiley   +1 more source

ERM Inhibition Confers Ferroptosis Resistance through ROS‐Induced NRF2 Signaling

open access: yesAdvanced Science, EarlyView.
ERM inhibition disrupts ERM‐actin interactions, elevating ROS and triggering KEAP1 degradation, which stabilizes and activates NRF2. Nuclear NRF2 induces cytoprotective genes, notably HMOX1, enhancing redox buffering and suppressing lipid peroxidation to resist erastin‐induced ferroptosis.
Menghao Qiao   +19 more
wiley   +1 more source

Low serum testosterone is associated with an increased risk of first-time renal calculi in men without testosterone replacement therapy. [PDF]

open access: yesInt J Impot Res
Thompson A   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy